Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Improvement of Axonal Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy After Intravenous Immunoglobulin Therapy

Improvement of Axonal Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy... EDITORIAL Improvement of Axonal Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy After Intravenous Immunoglobulin Therapy INCE THE FIRST CLEAR DESCRIPTIONS BY AUSTIN Most research has merely confirmed that inflammation in 1958, chronic inflammatory demyelin- plays a role in the disease. Genes encoding inflamma- ating polyneuropathy (CIDP) has emerged tory factors are upregulated in circulating lymphocytes as a definable, not uncommon, and treat- and monocytes in the blood and also in skin biopsy S able cause of chronic peripheral nerve dis- samples from patients with CIDP to a greater extent ease. After many different individual definitions and clas- than those from controls. Circulating B-cell responses sifications, an international consensus group set diagnostic to Epstein-Barr virus antigens (but not other herpes criteria that identify definite and probable cases, depend- virus antigens) are enhanced. Levels of the tumor ing on the severity of the neurophysiological abnormali- necrosis factor receptor 2 for tumor necrosis factor on T ties, and that distinguish typical symmetrical cases with cells are increased. Not unsurprisingly, because sensory and motor involvement and predominantly proxi- inflammation is enhanced in CIDP, there is evidence of mal weakness from various atypical cases with asym- impaired control of the immune response. T-cell http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Improvement of Axonal Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy After Intravenous Immunoglobulin Therapy

JAMA Neurology , Volume 68 (7) – Jul 1, 2011

Loading next page...
 
/lp/american-medical-association/improvement-of-axonal-function-in-patients-with-chronic-inflammatory-TGU2oZEvdc
Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/archneurol.2011.138
pmid
21747026
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Improvement of Axonal Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy After Intravenous Immunoglobulin Therapy INCE THE FIRST CLEAR DESCRIPTIONS BY AUSTIN Most research has merely confirmed that inflammation in 1958, chronic inflammatory demyelin- plays a role in the disease. Genes encoding inflamma- ating polyneuropathy (CIDP) has emerged tory factors are upregulated in circulating lymphocytes as a definable, not uncommon, and treat- and monocytes in the blood and also in skin biopsy S able cause of chronic peripheral nerve dis- samples from patients with CIDP to a greater extent ease. After many different individual definitions and clas- than those from controls. Circulating B-cell responses sifications, an international consensus group set diagnostic to Epstein-Barr virus antigens (but not other herpes criteria that identify definite and probable cases, depend- virus antigens) are enhanced. Levels of the tumor ing on the severity of the neurophysiological abnormali- necrosis factor receptor 2 for tumor necrosis factor on T ties, and that distinguish typical symmetrical cases with cells are increased. Not unsurprisingly, because sensory and motor involvement and predominantly proxi- inflammation is enhanced in CIDP, there is evidence of mal weakness from various atypical cases with asym- impaired control of the immune response. T-cell

Journal

JAMA NeurologyAmerican Medical Association

Published: Jul 1, 2011

References